Skip to main content
Erschienen in: World Journal of Urology 3/2009

01.06.2009 | Original Article

The value of newborn urinary proteome analysis in the evaluation and management of ureteropelvic junction obstruction: a cost-effectiveness study

verfasst von: Hrair-George O. Mesrobian

Erschienen in: World Journal of Urology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The cornerstone of management in newborns with ureteropelvic junction obstruction (UPJO) is serial imaging over time. Surgery is undertaken for disease progression. A marker of disease progression would select out those likely to progress for early surgery and diminish the intensity of imaging and follow-up in the remainder. Recently, urinary proteome analysis in the newborn has been reported to fulfill this aim. The objective of this study is to quantitatively evaluate the effect of this matrix of protein biomarkers on the overall cost-effectiveness (C-E) of UPJO evaluation and management.

Methods

A Markov process decision tree model (Tree Age Pro software, Boston, MA) is created to compare the current strategy (watchful waiting) to one incorporating a urine proteome analysis at birth as a marker of disease progression. The analysis includes the costs of surgery, imaging and office visits based on hospital charge data. We analyze a total of 53 variables.

Results

The incorporation of this marker of progression results on the average, in an incremental C-E gain of $8,000 per quality adjusted life year (QALY) per patient compared to the current strategy of watchful waiting. The results are not sensitive to variation of any of the probabilities including costs and quality of life parameters used for the base-case analysis.

Conclusions

The incorporation of urinary proteome analysis in the initial evaluation of UPJO significantly reduces costs and increases the QALYs in this patient population. The test increases the odds of detecting UPJO progression from 1:3 to 1:1, while improving the overall C-E. These findings justify continued research in this area which in addition may have important applications in evaluating treatment outcomes.
Literatur
1.
Zurück zum Zitat Dhillon HK (1998) Prenatally diagnosed hydronephrosis: the Great Ormond Street experience. BJU 81(2):39–44PubMedCrossRef Dhillon HK (1998) Prenatally diagnosed hydronephrosis: the Great Ormond Street experience. BJU 81(2):39–44PubMedCrossRef
2.
Zurück zum Zitat Ulman I, Jayanthi VR, Koff SA (2000) The long-term follow-up of newborns with severe unilateral hydronephrosis initially managed nonoperatively. J Urol 164:1101–1105PubMedCrossRef Ulman I, Jayanthi VR, Koff SA (2000) The long-term follow-up of newborns with severe unilateral hydronephrosis initially managed nonoperatively. J Urol 164:1101–1105PubMedCrossRef
3.
Zurück zum Zitat Fernbach SK, Maizels M, Conway JJ (1993) Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol 23:478–480PubMedCrossRef Fernbach SK, Maizels M, Conway JJ (1993) Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol 23:478–480PubMedCrossRef
4.
Zurück zum Zitat Palmer LS, Maizels M, Cartwright PC et al (1998) Surgery versus observation for managing obstructive grade 3 to 4 unilateral hydronephrosis: a report from the Society for Fetal Urology. J Urol 159:222–228PubMedCrossRef Palmer LS, Maizels M, Cartwright PC et al (1998) Surgery versus observation for managing obstructive grade 3 to 4 unilateral hydronephrosis: a report from the Society for Fetal Urology. J Urol 159:222–228PubMedCrossRef
5.
Zurück zum Zitat Ransley PG, Dhillon HK, Gordon I, Duffy PG, Dillon J, Barratt TM (1990) The postnatal management of hydronephrosis diagnosed by prenatal ultrasound. J Urol 144:584PubMed Ransley PG, Dhillon HK, Gordon I, Duffy PG, Dillon J, Barratt TM (1990) The postnatal management of hydronephrosis diagnosed by prenatal ultrasound. J Urol 144:584PubMed
6.
Zurück zum Zitat Hsieh MH, Meng MV (2007) Decision analysis and Markov modeling in urology. J Urol 178:1867–1874PubMedCrossRef Hsieh MH, Meng MV (2007) Decision analysis and Markov modeling in urology. J Urol 178:1867–1874PubMedCrossRef
7.
Zurück zum Zitat Mesrobian H-G (2005) Best strategy for evaluation and management of hydronephrosis in newborns and infants: a cost-effectiveness analysis based approach. Medical College of Wisconsin Library. Dissertation submitted to the faculty of the graduate school of Biomedical Sciences Mesrobian H-G (2005) Best strategy for evaluation and management of hydronephrosis in newborns and infants: a cost-effectiveness analysis based approach. Medical College of Wisconsin Library. Dissertation submitted to the faculty of the graduate school of Biomedical Sciences
8.
Zurück zum Zitat Birth Data from the National Center for Health Statistics (2003) vol 52 (10) Birth Data from the National Center for Health Statistics (2003) vol 52 (10)
9.
10.
Zurück zum Zitat Decramer S, Bascands J-L, Schanstra JP (2007) Non-invasive markers of ureteropelvic junction obstruction. World J Urol 25:457–465PubMedCrossRef Decramer S, Bascands J-L, Schanstra JP (2007) Non-invasive markers of ureteropelvic junction obstruction. World J Urol 25:457–465PubMedCrossRef
11.
Zurück zum Zitat Tengs TO, Wallace A (2000) One thousand health-related quality of life estimates. Medical Care (38):583–637 Tengs TO, Wallace A (2000) One thousand health-related quality of life estimates. Medical Care (38):583–637
12.
Zurück zum Zitat Drummond MF (1996) Guidelines for authors and peer reviewers of economic submission to the BMJ. BMJ 313:275–283PubMed Drummond MF (1996) Guidelines for authors and peer reviewers of economic submission to the BMJ. BMJ 313:275–283PubMed
Metadaten
Titel
The value of newborn urinary proteome analysis in the evaluation and management of ureteropelvic junction obstruction: a cost-effectiveness study
verfasst von
Hrair-George O. Mesrobian
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0355-z

Weitere Artikel der Ausgabe 3/2009

World Journal of Urology 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.